Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Apr;121(4):940-46.e3.
doi: 10.1016/j.jaci.2008.01.013. Epub 2008 Mar 4.

Filaggrin null mutations and childhood atopic eczema: a population-based case-control study

Sara J Brown  1 , Caroline L Relton, Haihui Liao, Yiwei Zhao, Aileen Sandilands, Ian J Wilson, John Burn, Nick J Reynolds, W H Irwin McLean, Heather J Cordell
Affiliations

Filaggrin null mutations and childhood atopic eczema: a population-based case-control study

Sara J Brown et al. J Allergy Clin Immunol. 2008 Apr.

Abstract

Background: Null mutations within the filaggrin gene (FLG) are associated with moderate-to-severe atopic eczema; their role in mild-to-moderate eczema in the general population is unknown.

Objective: We sought to investigate the significance of 5 common FLG null mutations in childhood atopic eczema in an unselected population cohort.

Methods: Eight hundred eleven English children aged 7 to 9 years were screened for FLG mutations. Eczema cases were defined by using United Kingdom diagnostic criteria and skin examination. Asthma and seasonal rhinitis cases were defined by parental questionnaire. Association between phenotype and genotype was investigated using Fisher exact test and logistic regression analysis.

Results: The 12-month period prevalence of atopic eczema was 24.2% (95% CI, 21.2% to 27.2%), with 96% (115/120) of cases having mild-to-moderate disease. The combined null genotype (carriage of > or = 1 FLG mutations) was significantly associated with atopic eczema (P = 1.2 x 10(-4)). The odds ratio (OR) for individuals carrying 2 null mutations was 26.9 (95% CI, 3.3-217.1), but heterozygote carriers showed no significant increase in risk (OR, 1.2; 95% CI, 0.7-1.9). Eight of 190 eczema cases (4.2%) carried 2 FLG null mutations and thus might be attributed to filaggrin deficiency. Asthma in the context of eczema showed significant association with the FLG null mutations (P = 7.1 x 10(-4)). There was no association of FLG with asthma independent of eczema (P = .15) and no association with seasonal rhinitis (P = .66).

Conclusion: FLG null mutations are significantly associated with mild-to-moderate atopic eczema in childhood, with a recessive pattern of inheritance.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

IMcL has filed patents relating to genetic testing and therapy development aimed at the filaggrin gene.

The other authors have no conflict of interest.

Figures

Figure 1
Figure 1. Flow diagram showing recruitment of children to the study.
Figure 2
Figure 2. Logistic regression analysis to estimate odds of disease (atopic eczema) with FLG null mutations comparing genotype and allele-based models.
The 95% confidence intervals are as follows: Genotype model heterozygotes vs wild type 0.7-1.9; homozygote mutants vs wild type 3.3-217.1. Allele model 1.2-8.6.The likelihood ratio test, to test whether the allele model can be nested in full within the genotype model of disease, shows that the genotype model fits the data significantly better (p=1.8x10-3).
See this image and copyright information in PMC

References

    1. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113:832–6. - PubMed
    1. Chamlin SL, Cella D, Frieden IJ, Williams ML, Mancini AJ, Lai JS, et al. Development of the Childhood Atopic Dermatitis Impact Scale: initial validation of a quality-of-life measure for young children with atopic dermatitis and their families. J Invest Dermatol. 2005;125:1106–11. - PubMed
    1. Hudson TJ. Skin barrier function and allergic risk. Nat Genet. 2006;38:399–400. - PubMed
    1. Taieb A, Hanifin J, Cooper K, Bos JD, Imokawa G, David TJ, et al. J Allergy Clin Immunol; Proceedings of the 4th Georg Rajka International Symposium on Atopic Dermatitis; Arcachon, France. September 15-17, 2005; 2006. pp. 378–90. - PubMed
    1. Hahn EL, Bacharier LB. The atopic march: the pattern of allergic disease development in childhood. Immunol Allergy Clin North Am. 2005;25:231–46, v. - PubMed

Publication types

MeSH terms